ELIGARD KIT Drug Patent Profile

Which patents cover Eligard Kit, and what generic alternatives are available?

Eligard Kit is a drug marketed by Tolmar and is included in four NDAs. There are three patents protecting this drug.

This drug has thirty patent family members in twenty-five countries.

The generic ingredient in ELIGARD KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eligard Kit

A generic version of ELIGARD KIT was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for ELIGARD KIT

International Patents:	30
US Patents:	3
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	2
Clinical Trials:	55
DailyMed Link:	ELIGARD KIT at DailyMed

Recent Clinical Trials for ELIGARD KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ontario Clinical Oncology Group (OCOG)	PHASE2
TOLMAR PHARMACEUTIQUES CANADA, INC.	PHASE2
Ontario Clinical Oncology Group (OCOG) - McMaster University	PHASE2

See all ELIGARD KIT clinical trials

Pharmacology for ELIGARD KIT

Drug Class	Gonadotropin Releasing Hormone Receptor Agonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Agonists

US Patents and Regulatory Information for ELIGARD KIT

ELIGARD KIT is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021343-001	Jan 23, 2002		RX	Yes	Yes
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002		RX	Yes	Yes
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021731-001	Dec 14, 2004		RX	Yes	Yes			Y	Y
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes			Y	Y
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021343-001	Jan 23, 2002		RX	Yes	Yes				Y

Expired US Patents for ELIGARD KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003

International Patents for ELIGARD KIT

See the table below for patents covering ELIGARD KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	649662
European Patent Office	0537559	Compositions polymériques utilisables comme implants à libération controlée (Polymeric compositions useful as controlled release implants)
European Patent Office	4461333
Luxembourg	91193
Spain	2113906
Norway	911277

Supplementary Protection Certificates for ELIGARD KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0436667	C300204	Netherlands
0436667	91193	Luxembourg		91193, EXPIRES: 20140927

ELIGARD KIT (leuprolide acetate): Market dynamics and financial trajectory

Last updated: April 24, 2026

What is ELIGARD KIT’s market position?

ELIGARD KIT is an injectable leuprolide acetate androgen-deprivation therapy (ADT) used primarily in prostate cancer indications. In the current US market structure, ELIGARD competes in a crowded ADT landscape that includes other luteinizing hormone–releasing hormone (LHRH) injectables and depots, plus payer-driven switching toward products with stronger formulary placement and lower net cost.

Key structural points that drive ELIGARD’s dynamics:

• Class competition is intense: ADT therapies are mature, and payers push for preferred agents through rebates and contracting.
• Depot lifecycle pressure: formulations face pricing pressure over time as inventories age and competitors secure broader coverage.
• Patent and exclusivity maturity: most market value for mature biologics/small-molecule depots shifts toward net price management and share defense rather than new-to-market uptake.

What market dynamics shape demand for ELIGARD?

Demand for ADT injectables is largely anchored to:

• Incident prostate cancer treatment pathways (new and continuing therapy cohorts).
• Switching behavior based on payer coverage, administration logistics, and patient preference for dosing schedules.
• Institutional procurement mechanics: hospital and outpatient infusion centers negotiate based on contract status and administrative burden.

The competitive and contracting levers that typically move net sales for ELIGARD-like products are:

• Formulary position and prior authorization requirements, which directly affect access.
• Net-to-gross compression from rebates and wholesaler incentives (net sales can fall even when list price holds).
• Portfolio substitution among LHRH depot therapies at equivalent dosing intervals (monthly, 3-month, 4-month, 6-month where available across competitors).

How does payer contracting typically impact ELIGARD financial trajectory?

For mature oncology depot injectables, the financial path is usually defined by:

• Initial share defense post–exclusivity window, followed by volume elasticity loss as preferred products tighten.
• Net price decline driven by rebate escalation and competitive interchange.
• Channel normalization: reduced “pull-through” from distributors once contracts renew and shelf management stabilizes.

For ELIGARD specifically, the practical implication is that financial trajectory is more sensitive to:

• rebate rate changes,
• formulary moves,
• and contract renewals, than to any single marketing action or clinical differentiation claim.

What financial drivers drive ELIGARD net sales over time?

The net sales formula for a depot injectable in a high-contract oncology class compresses into three dominant drivers:

1) Unit volume
Determined by treated patient population and persistence (time on therapy), net of switching and dosing schedule substitution.

2) Net price
Determined by rebates, wholesaler terms, and payer contracting.

3) Mix
Depot duration and pack configuration changes the effective revenue per treated patient and can mask unit declines or amplify them.

ELIGARD kit performance is therefore typically best explained by:

• persistence and share stability (volume driver),
• payer preference (price driver),
• and kit strength/duration mix (mix driver).

What are the key market inflection risks?

The main risks to financial performance for ELIGARD-like depots are:

• Preferred competitor substitution: if a rival depot secures or expands formulary coverage, patients can shift quickly due to class interchangeability.
• Administration and workflow constraints: clinic and pharmacy workflow affects uptake for any injectable depot.
• Rebate pressure: even stable demand can produce lower net sales through higher rebates at renewal.
• Inventory and channel timing: distributor ordering patterns can create quarter-to-quarter volatility in reported sales.

What does the competitive landscape imply for ELIGARD’s trajectory?

In mature oncology ADT classes:

• Competitors with stronger formulary status generally capture incremental share even when clinical outcomes are comparable across products.
• Financial performance tends to follow a steady-state then compression pattern rather than sustained expansion.
• Growth (when it appears) typically comes from mix shifts and contracting-driven capture, not from large net new penetration into the treated population.

How should investors and R&D stakeholders read ELIGARD financial signals?

For a product like ELIGARD kit, financial trajectory signals to watch are:

• Net sales trend vs. unit trend: if units hold but sales fall, net price compression is dominating.
• Quarterly volatility: distributor ordering and inventory true-ups can distort near-term read-through.
• Formulary status changes: even small formulary shifts can translate into meaningful volume impacts across a class.

Where does ELIGARD fit in the broader ADT market value chain?

ELIGARD’s position is defined by being an established ADT depot, meaning its value contribution tends to:

• monetize an existing patient base with ongoing treated cohorts,
• face continual payer contracting pressure,
• and require active share retention against preferred agents.

From an investment and R&D standpoint, that usually means:

• incremental product differentiation matters less than commercial execution,
• and long-term value depends on sustaining net price and maintaining coverage rather than expecting new uptake curves.

What commercialization outcomes usually follow for mature depot ADT products like ELIGARD?

Observed outcomes across mature depot injectables typically include:

• Net sales plateau after exclusivity and competitive onboarding stabilize.
• Margin pressure as rebate rates escalate.
• Share erosion as preferred competitors expand coverage.
• Lifecycle management via mix and channel optimization.

What are the actionable takeaways for business planning around ELIGARD?

• Treat ELIGARD as a contracting and access-driven product; model scenarios on rebate and formulary outcomes rather than assuming demand growth.
• Monitor whether performance is being driven by mix (kit composition) versus true unit share.
• Assume competitive substitution risk persists and build planning buffers for net sales compression around contract renewals.

---

Key Takeaways

• ELIGARD KIT operates in a mature, payer-controlled ADT market where formulary preference and net pricing matter more than uptake growth.
• Financial trajectory is typically governed by net price compression, rebate escalation, and competitor substitution, with only limited ability to expand treated patient penetration.
• Near-term volatility can reflect channel inventory and ordering patterns, while longer-term performance tracks contracting stability and mix.

FAQs

1) Is ELIGARD KIT growth driven by new patient uptake?
In mature ADT markets, growth is more commonly driven by contracting access, formulary placement, and mix shifts than by new patient penetration.

2) What hurts net sales for ELIGARD in the ADT class?
Higher rebates, formulary displacement, and competitive substitution tend to reduce net price and volume at the same time.

3) What improves ELIGARD financial outcomes?
Sustained formulary status, stable channel demand, and favorable mix across depot/pack configurations.

4) Why can ELIGARD sales fluctuate quarter to quarter?
Distributor ordering and inventory rebalancing can shift revenue timing even when underlying patient demand is stable.

5) How should stakeholders model ELIGARD revenue risk?
Use scenarios built on net price and formulary access changes, not on large biologic-style market expansion assumptions.

---

References

[1] ELIGARD KIT (leuprolide acetate) prescribing information, including indications and dosing overview.